There were 206 male patients in this study with criteria being ≥ 50 years of age as well as an IPSS score of ≥ 13. The prostate vol-ume had to be between 30-80cc and the peak flow rate ≤ 12 ml/s. Pa-tients were randomized to either PUL or control. Both the patients and the assessors were blinded to treatment arm for 3 months. After PUL, a minimally invasive surgery, is implemented, permanent im-plants retract the lateral loves to open the prostatic fossa enlarging the uretheral lumen.
After 5 years, 104 patients were remaining. IPSS (7.6 or 36% from baseline), QOL (2.3 or 50% from baseline), and Qmax ( 3.5mL/s or 44% from baseline) remain improved and re-treatment is rare (2% to 3% per year over 5 years). Local anesthesia was well tolerated. PUL avoided incontinence and sexual side effects or sexual dysfunc-tion including ejaculatory dysfunction. It took 8.6 days to recover to normal functionality with rapid symptom relief. 68% of the patients re-ceived no post-operative catheter. After one year, a cystoscopy was conducted and videos were reviewed showing no evidence of encrus-tation on implants in the prostatic urethra. Overall, there was an im-provement in symptoms, quality of life, and flow durable over the 5 years due to this minimally invasive surgery.
Presented By: Claus Roehrborn, MD
Authors: Claus Roehrborn, MD, Neal Shore, Steven Gange, Daniel B Rukstalis,
Affiliation: UT Southwestern Medical Center, Atlantic Urology Clin-ics, Department of Urology, Wake Forest University
Written By: Kheira Bettir, University of Irvine, California for UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA